AKArmel Hervé Nwabo Kamdje

Armel Hervé Nwabo Kamdje

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Armel Hervé Nwabo Kamdje has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy

    by Armel Hervé Nwabo Kamdje, Hervet Paulain Dongmo Fogang, Patrice N. Mimche

    Major epigenetic changes are associated with carcinogenesis, including aberrant DNA methylations and post-translational modifications of histone. Indeed evidence accumulated in recent years indicates that inactivating DNA hypermethylation preferentially targets the subset of polycomb group (PcG) genes that are regulators of developmental processes. Conversely, activating DNA hypomethylation targets oncogenic signaling pathway genes, but outcomes of both events lead in the overexpression of oncogenic signaling pathways that contribute to the stem-like state of cancer cells. On the basis of recent evidence from population-basedclinical and experimental studies, we hypothesize that factors associated with risk for developing a hematologic malignancy (HM), such as metabolic syndrome and chronic inflammation, may trigger epigenetic mechanisms to increase the transcriptional expression of oncogenes and activate oncogenic signaling pathways. Signaling pathways associated with such risk factors include but are not limited to pro-inflammatory nuclear factor κB (NF-κB) and mitogenic, growth, and survival Janus kinase (JAK) intracellular non-receptor tyrosine kinase-triggered pathways. The latter includes signaling pathways such as transducer and activator of transcription (STAT), Ras GTPases/mitogen-activated protein kinases (MAPKs)/extracellular signal-related kinases (ERKs), phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and β-catenin pathways. Recent findings on epigenetic mechanisms at work in the biology of cancer and in HMs and their importance in the etiology and pathogenesis of these diseases are herein summarized and discussed. Furthermore, the role of epigenetic processes in the determination of biological identity, the consequences for interindividual variability in disease clinical profile, and the potential of epigenetic drugs in HMs are also considered.


  • Open Access

    Role of signaling pathways in the interaction between microbial, inflammation and cancer

    by Armel Hervé Nwabo Kamdje, Richard Tagne Simo, Hetvet Paulain Fogang Dongmo, Amel Renaud Bidias, Palmer Masumbe Netongo

    Microbial-induced inflammation serves a dual role, safeguarding against pathogens but also posing a risk of secondary harm to host tissues, potentially leading to fibrosis and cancer. Beyond traditional pathogens, gut microbiota, the mutualistic microorganisms inhabiting the gastrointestinal tract, crucial for digestion, immunity, and cancer prevention, can incite inflammation-related cancer when their microenvironment undergoes changes. Recent research reveals that microbiota members like Escherichia coli and other genotoxic pathogens can induce DNA damage across various cell types. Chronic infections involving microbiota members like Helicobacter spp., linked to liver, colorectal, cervical cancers, and lymphoma, can activate carcinogenic processes. Inflammatory responses, driven by immune cells releasing inflammatory molecules like macrophage migration inhibitory factor (MMIF), superoxide peroxynitrite, pro-inflammatory cytokines, adhesion molecules, and growth factors, contribute to DNA damage and oncogenic mutations accumulation. This microenvironment further supports neoplastic cell survival and proliferation. This summary discusses the involvement of inflammatory pathways in microbial-triggered carcinogenesis and the potential role of microbiota modulation in cancer prevention.


  • Open Access

    Correction: Effects of Vitellaria paradoxa (C.F. Gaertn.) Aqueous leaf extract administration on Salmonella typhimurium-infected rats

    by Siméon Pierre Chegaing Fodouop, Sedric Donald Tala, Lunga Paul Keilah, Norbert Kodjio, Mefokou Didiane Yemele, Armel Herve Nwabo Kamdje, Bridget Nji-Kah, Joseph Tchoumboue, Donatien Gatsing


  • Open Access

    Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential

    by Armel H. Nwabo Kamdje, Paul F. Seke Etet, Maulilio J. Kipanyula, Lorella Vecchio, Richard Tagne Simo, Alfred K. Njamnshi, Kiven E. Lukong, Patrice N. Mimche

    The tumor microenvironment fuels tumorigenesis and induces the development of resistance to anticancer drugs. A growing number of reports support that the tumor microenvironment mediates these deleterious effects partly by overexpressing insulin-like growth factor 1 (IGF-1). IGF-1 is known for its role to support cancer progression and metastasis through the promotion of neovascularization in transforming tissues, and the promotion of the proliferation, maintenance and migration of malignant cells. Anti-IGF therapies showed potent anticancer effects and the ability to suppress cancer resistance to various chemotherapy drugs in in vivo and in vitro preclinical studies. However, high toxicity and resistance to these agents are increasingly being reported in clinical trials. We review data supporting the notion that tumor microenvironment mediates tumorigenesis partly through IGF-1 signaling pathway. We also discuss the therapeutic potential of IGF-1 receptor targeting, with special emphasis on the ability of IGF-R silencing to overcome chemotherapy drug resistance, as well as the challenges for clinical use of anti-IGF-1R therapies.


  • Open Access

    Prevalence of precancerous cervical lesions and high-risk human papillomavirus types in Yaounde, Cameroon

    by Richard Tagne Simo, Arsène G Djoko Nono, Hervet Paulin Fogang Dongmo, Paul F Seke Etet, Bertrand Kiafon Fonyuy, Armel H Nwabo Kamdje, Nicolas Njintang Yanou, Phélix Bruno Telefo

    Introduction: Various Human papillomavirus (HPV) types cause cervical cancer, and represent the primary cause of cancer death in Africa and the second cause of most common cancers in Cameroon. Herein, we determined the prevalence of high-risk HPV types in women and associated cervical cytologic abnormalities in Yaounde, Cameroon. Methodology: A cross-sectional study targeting HPV-positive women aged 20 and over was conducted between March and June 2020 at the Saint Martin de Porres’ Health Centre in Yaounde. HPV tests were performed by PCR for detection of HPVs 16, 18, 33, and 45. The test was performed on 616 women using exfoliated cell specimens; then, we processed on cytological diagnosis with Pap smears on HPV positive specimens. Results: The HPV types tested were detected in 137 participants, of which 38.7% with multiple HPV infections, and the remaining part with single HPV infections of type HPV 16 (28.5%), HPV 18 (17.5%), HPV 33 (10.2%), and HPV 45 (5.1%). Cervical cytologic abnormalities were found in 69.34% of participants including: LSIL (49.63%), HSIL (15.32%), ASC-US (3.66%) and AGC (0.73%). Co-infections with HPV 16 and HPV 18 were significantly associated with HSIL (p = 0.001) lesions, while HPV 45 was more common in participants with normal cytology (p = 0.001). Cervical lesion occurrence was significantly associated with the number of sexual partners (p = 0.02) and history of oral contraceptive pill use (p = 0.001). Conclusions: Our results suggest that HPV 16 and 18 are predominant in Yaounde, and are associated with more severe precancerous lesions.


  • Open Access

    Influence of HIV infection on the distribution of high-risk HPV types among women with cervical precancerous lesions in Yaounde, Cameroon

    by Richard Tagne Simo, F.B. Kiafon, C. Nangue, André P. Goura, Jackson L. Ebune, Moki C. Usani, Armel H. Nwabo Kamdje, Paul F. Seke Etet, Phélix B. Telefo


  • Open Access

    Awareness of Breast Cancer Screening among the Medical and General Population of the North Region of Cameroon

    by Richard Tagne Simo, Erika Myriam Baiguerel, Armel Hervé Nwabo Kamdje, Paul Faustin Seke Etet, Mohamadou Ahmadou, Charlette Nangue, Phelix Bruno Telefo

    Breast cancer has become a real public health problem in Cameroon, particularly in rural areas due to late diagnosis, resulting partly from the absence of national screening programs. This work is aimed at assessing breast cancer awareness in the North Region of Cameroon. Participants were selected in six health centers surrounding the rural area of Garoua, North Region, Cameroon, and administered a questionnaire aimed at assessing their awareness about breast cancer risk factors and screening. Out of the 475 women (including 37 medical personnel) interviewed, 45.5% attended at least secondary school; 91.3% were aware of the disease with the main sources of information from those around them (64.8%), media (46.5%), and health professionals in health facilities (42.7%). 23.3% had misconceptions and myth-based ideas on the origin of the disease. Ignorance was the main reason preventing the performance of breast self-examination, and the high cost prevents individuals from going for mammography. The highest awareness rate was observed in employed women with higher level of education. Our study highlights the need to raise awareness among the populations in North Region, Cameroon, about the risk factors and clinical signs of breast cancer and the importance of screening practice for early diagnosis of breast cancer.


  • Open Access

    Breast cancer awareness and screening practice amongst health personnel and general population of the littoral region of Cameroon

    by Mohamadou Halmata, Richard Tagne Simo, Grace Nganwa Kembaou, Erika Myriam Baiguerel, Lydiane C.C. Ndopwang, Armel Herve Nwabo Kamdje, Phelix Bruno Telefo, Charlette Nangue, Elias Nchiwan Nukenine


  • Open Access

    A new phenyl alkyl ester and a new combretin triterpene derivative from Combretum fragrans F. Hoffm (Combretaceae) and antiproliferative activity

    by Isaac Silvère Gade, Corinne Chadeneau, Richard Tagne Simo, Emmanuel Talla, Alex De Theodore Atchade, Paule Seité, Brigitte Vannier, Sophie Laurent, Celine Henoumont, Armel H. Nwabo Kamdje, et al.

    This work concerns the isolation and structure elucidation of compounds obtained from the extract of leaves and stem bark of Combretum fragrans F. Hoffm. Both extracts and some isolated compounds were tested for antiproliferative activity on glioblastoma (U87MG and C6 cells) and prostate (PC-3 cells) cancer cell lines using XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) assay. The dichloromethane/methanol (1:1) extract of the leaves led to the isolation of two new compounds such as fragransinate (1) and combretin C (2), alongside five known compounds such as combretin A (3), belamcanidin (4), cirsilineol (5), velutin (6), and a mixture of β-sitosterol-3-O-β-d-glucopyranoside (10a) and stigmasterol-3-O-β-d-glucopyranoside (10b), whereas the methanol extract of the stem bark led to the isolation of three known compounds betulinic acid (7), bellericagenin B (8), and a mixture of β-sitosterol (9a) and stigmasterol (9b). The structure of compounds was elucidated by nuclear magnetic resonance and mass spectrometry data. The methanol extract of the stem bark showed a powerful antiproliferative activity on all tested cells, as well as the extract of leaves which also showed important cytotoxicity effect. Compound (3) showed good antiproliferative activity particularly on U87MG and PC-3 cells, whereas compound (5) exhibits moderated activity. Compounds (2) and (8) were not active on all tested cells.


  • Open Access

    Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects

    by Armel H. Nwabo Kamdje, Paul F. Seke Etet, Richard Simo Tagne, Lorella Vecchio, Kiven Erique Lukong, Mauro Krampera

    The role of mesenchymal stromal cells (MSCs) in the tumor microenvironment is well described. Available data support that MSCs display anticancer activities, and that their reprogramming by cancer cells in the tumor microenvironment induces their switch toward pro-tumorigenic activities. Here we discuss the recent evidence of pro-tumorigenic effects of stromal cells, in particular (i) MSC support to cancer cells through the metabolic reprogramming necessary to maintain their malignant behavior and stemness, and (ii) MSC role in cancer cell immunosenescence and in the establishment and maintenance of immunosuppression in the tumor microenvironment. We also discuss the mechanisms of tumor microenvironment mediated reprogramming of MSCs, including the effects of hypoxia, tumor stiffness, cancer-promoting cells, and tumor extracellular matrix. Finally, we summarize the emerging strategies for reprogramming tumor MSCs to reactivate anticancer functions of these stromal cells.